Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

被引:2438
作者
Iwai, Y
Ishida, M
Tanaka, Y
Okazaki, T
Honjo, T
Minato, N [1 ]
机构
[1] Kyoto Univ, Grad Sch Biostudies, Dept Immunol & Cell Biol, Kyoto 6068501, Japan
[2] Japan Sci & Technol Corp, Grad Sch Med, Dept Med Chem, Kyoto 6068501, Japan
[3] Japan Sci & Technol Corp, PRESTO, Kyoto 6068501, Japan
关键词
D O I
10.1073/pnas.192461099
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
PD-1 is a receptor of the Ig superfamily that negatively regulates T cell antigen receptor signaling by interacting with the specific ligands (PD-L) and is suggested to play a role in the maintenance of self-tolerance. In the present study, we examined possible roles of the PD-1/PD-L system in tumor immunity. Transgenic expression of PD-L1, one of the PD-L, in P815 tumor cells rendered them less susceptible to the specific T cell antigen receptor-mediated lysis by cytotoxic T cells in vitro, and markedly enhanced their tumorigenesis and invasiveness in vivo in the syngeneic hosts as compared with the parental tumor cells that lacked endogenous PD-L. Both effects could be reversed by anti-PD-L1 Ab. Survey of murine tumor lines revealed that all of the myeloma cell lines examined naturally expressed PID-L1. Growth of the myeloma cells in normal syngeneic mice was inhibited significantly albeit transiently by the administration of anti-PD-L1 Ab in vivo and was suppressed completely in the syngeneic PD-1-deficient mice. These results suggest that the expression of PD-L1 can serve as a potent mechanism for potentially immunogenic tumors to escape from host immune responses and that blockade of interaction between PD-1 and PD-L may provide a promising strategy for specific tumor immunotherapy.
引用
收藏
页码:12293 / 12297
页数:5
相关论文
共 25 条
[11]   PD-L2 is a second ligand for PD-I and inhibits T cell activation [J].
Latchman, Y ;
Wood, CR ;
Chernova, T ;
Chaudhary, D ;
Borde, M ;
Chernova, I ;
Iwai, Y ;
Long, AJ ;
Brown, JA ;
Nunes, R ;
Greenfield, EA ;
Bourque, K ;
Boussiotis, VA ;
Carter, LL ;
Carreno, BM ;
Malenkovich, N ;
Nishimura, H ;
Okazaki, T ;
Honjo, T ;
Sharpe, AH ;
Freeman, GJ .
NATURE IMMUNOLOGY, 2001, 2 (03) :261-268
[12]   Enhancement of antitumor immunity by CTLA-4 blockade [J].
Leach, DR ;
Krummel, MF ;
Allison, JP .
SCIENCE, 1996, 271 (5256) :1734-1736
[13]   Immunological studies on PD-1-deficient mice: implication of PD-1 as a negative regulator for B cell responses [J].
Nishimura, H ;
Minato, N ;
Nakano, T ;
Honjo, T .
INTERNATIONAL IMMUNOLOGY, 1998, 10 (10) :1563-1572
[14]   PD-1: an inhibitory immunoreceptor involved in peripheral tolerance [J].
Nishimura, H ;
Honjo, T .
TRENDS IN IMMUNOLOGY, 2001, 22 (05) :265-268
[15]   Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice [J].
Nishimura, H ;
Okazaki, T ;
Tanaka, Y ;
Nakatani, K ;
Hara, M ;
Matsumori, A ;
Sasayama, S ;
Mizoguchi, A ;
Hiai, H ;
Minato, N ;
Honjo, T .
SCIENCE, 2001, 291 (5502) :319-322
[16]   Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor [J].
Nishimura, H ;
Nose, M ;
Hiai, H ;
Minato, N ;
Honjo, T .
IMMUNITY, 1999, 11 (02) :141-151
[17]  
RAMARATHINAM L, 1995, J IMMUNOL, V155, P5323
[18]   Cancer vaccines based on the identification of genes encoding cancer regression antigens [J].
Rosenberg, SA .
IMMUNOLOGY TODAY, 1997, 18 (04) :175-182
[19]   The complexities of T-cell co-stimulation: CD28 and beyond [J].
Sperling, AI ;
Bluestone, JA .
IMMUNOLOGICAL REVIEWS, 1996, 153 :155-182
[20]   ICOS is essential for effective T-helper-cell responses [J].
Tafuri, A ;
Shahinian, A ;
Bladt, F ;
Yoshinaga, SK ;
Jordana, M ;
Wakeham, A ;
Boucher, LM ;
Bouchard, D ;
Chan, VSF ;
Duncan, G ;
Odermatt, B ;
Ho, A ;
Itie, A ;
Horan, T ;
Whoriskey, JS ;
Pawson, T ;
Penninger, JM ;
Ohashi, PS ;
Mak, TW .
NATURE, 2001, 409 (6816) :105-109